Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John T Reilly

Showing results (61-70 of 72) with videos related to

Pageof 8
Sort By:
Blood|May 3, 2008
MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohortPhilip A Beer, Peter J Campbell, Linda M Scott, et al.
Haematologica|December 5, 2015
STAT1 activation in association with JAK2 exon 12 mutationsAnna L Godfrey, Edwin Chen, Charles E Massie, et al.
British Journal of Haematology|August 23, 2014
Monitoring of chimerism following allogeneic haematopoietic stem cell transplantation (HSCT): technical recommendations for the use of short tandem repeat (STR) based techniques, on behalf of the United Kingdom National External Quality Assessment Service for Leucocyte Immunophenotyping Chimerism Working GroupJordan R Clark, Stuart D Scott, Andrea L Jack, et al.
British Journal of Haematology|June 2, 2012
Guideline for the diagnosis and management of myelofibrosisJohn T Reilly, Mary Frances McMullin, Philip A Beer, et al.
Blood|May 10, 2007
Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panelAyalew Tefferi, Juergen Thiele, Attilio Orazi, et al.
Blood|August 18, 2012
JAK2V617F homozygosity arises commonly and recurrently in PV and ET, but PV is characterized by expansion of a dominant homozygous subcloneAnna L Godfrey, Edwin Chen, Francesca Pagano, et al.
British Journal of Haematology|March 25, 2010
Guideline for investigation and management of adults and children presenting with a thrombocytosisClaire N Harrison, David Bareford, Nauman Butt, et al.
Blood|July 29, 2006
Mutation of JAK2 in the myeloproliferative disorders: timing, clonality studies, cytogenetic associations, and role in leukemic transformationPeter J Campbell, E Joanna Baxter, Philip A Beer, et al.
Lancet (London, England)|December 6, 2005
Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective studyPeter J Campbell, Linda M Scott, Georgina Buck, et al.
Blood|November 19, 2005
V617F mutation in JAK2 is associated with poorer survival in idiopathic myelofibrosisPeter J Campbell, Martin Griesshammer, Konstanze Döhner, et al.
Pageof 8

Showing results (61-70 of 72) with videos related to

Sort By:
Pageof 8
Blood|May 3, 2008
MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohortPhilip A Beer, Peter J Campbell, Linda M Scott, et al.
Haematologica|December 5, 2015
STAT1 activation in association with JAK2 exon 12 mutationsAnna L Godfrey, Edwin Chen, Charles E Massie, et al.
British Journal of Haematology|August 23, 2014
Monitoring of chimerism following allogeneic haematopoietic stem cell transplantation (HSCT): technical recommendations for the use of short tandem repeat (STR) based techniques, on behalf of the United Kingdom National External Quality Assessment Service for Leucocyte Immunophenotyping Chimerism Working GroupJordan R Clark, Stuart D Scott, Andrea L Jack, et al.
British Journal of Haematology|June 2, 2012
Guideline for the diagnosis and management of myelofibrosisJohn T Reilly, Mary Frances McMullin, Philip A Beer, et al.
Blood|May 10, 2007
Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panelAyalew Tefferi, Juergen Thiele, Attilio Orazi, et al.
Blood|August 18, 2012
JAK2V617F homozygosity arises commonly and recurrently in PV and ET, but PV is characterized by expansion of a dominant homozygous subcloneAnna L Godfrey, Edwin Chen, Francesca Pagano, et al.
British Journal of Haematology|March 25, 2010
Guideline for investigation and management of adults and children presenting with a thrombocytosisClaire N Harrison, David Bareford, Nauman Butt, et al.
Blood|July 29, 2006
Mutation of JAK2 in the myeloproliferative disorders: timing, clonality studies, cytogenetic associations, and role in leukemic transformationPeter J Campbell, E Joanna Baxter, Philip A Beer, et al.
Lancet (London, England)|December 6, 2005
Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective studyPeter J Campbell, Linda M Scott, Georgina Buck, et al.
Blood|November 19, 2005
V617F mutation in JAK2 is associated with poorer survival in idiopathic myelofibrosisPeter J Campbell, Martin Griesshammer, Konstanze Döhner, et al.
Pageof 8